Background {#Sec1}
==========

Emerging studies have demonstrated that deregulated expression of microRNAs (miRNAs) correlates with cancer prognosis because of the distinct expression profiles of these miRNAs in cancerous tissues compared with normal tissues \[[@CR1]--[@CR3]\]. A large number of studies have put particular emphasis on the upregulated expression of various miRNAs that are usually associated with poor prognosis in malignant neoplasms, known as 'hazardous miRNAs' \[[@CR1]--[@CR5]\]. However, some recent studies have transferred attention to the downregulated expression of several miRNAs that are associated with an unfavorable cancer prognosis \[[@CR5]--[@CR7]\], which are categorized as 'protective miRNAs' and are much less common than hazardous miRNAs. In these reported protective miRNAs, miR-145 has been studied relatively intensively and thoroughly for cancer prognosis.

The anti-tumor effects of miR-145 with various mechanisms have been demonstrated by abundant clinical and basic studies \[[@CR8]--[@CR11]\]. In hepatocellular carcinoma (HCC), miR-145 was found to target a number of genes along the signaling pathway of insulin-like growth factor (IGF), including IGF-1 receptor, insulin receptor substrate-1 (IRS-1), and IRS-2, all of which are directly downregulated by miR-145 \[[@CR8]\]. Law *et al*. also confirmed that miR-145 modulates the IGF signaling pathway by reducing its downstream mediator, the active β-catenin \[[@CR9]\]. In addition, p53 can induce miR-145 by binding directly to its promoter, after which miR-145 can silence c-Myc, demonstrating the role of miR-145 in p53-mediated c-Myc repression \[[@CR10]\]. In head and neck squamous cell carcinoma (SCC), miR-145 also can target the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects \[[@CR11]\] (Figure [1](#Fig1){ref-type="fig"}).Figure 1**Reported mechanisms for the anti-tumor effect and expression regulation of microRNA-145 (miR-145).**

As a tumor suppressor, miR-145 has been reported to have downregulated expression in various cancer tissues, although the targets of miR-145 have not been definitively identified \[[@CR8]--[@CR11]\]. A number of studies have shown significant associations between low miR-145 expression and poor cancer prognosis, but other studies did not find any significant association, and still others showed a negative correlation \[[@CR12], [@CR13]\] that might cast doubt on the anti-oncogenic role of miR-145. However, in spite of these contradictory results, miR-145 is still an attractive tumor biomarker with considerable prognostic value, and deserves to be further investigated. Therefore, we conducted a meta-analysis to clarify the preliminary predictive value of miR-145 in tumor prognoses.

Methods {#Sec2}
=======

Search strategy, eligibility criteria, and data extraction {#Sec3}
----------------------------------------------------------

We performed this meta-analysis following the guidelines of the Meta-analysis of Observational Studies in Epidemiology group (MOOSE) \[[@CR14]\]. Because newly published original works may get overlooked, we searched PubMed, EMBASE, and Web of Science up to March 2014 to identify relevant studies. Several combinations of the following keywords were simultaneously applied: 'cancer' , 'carcinoma' , 'neoplasm' , 'tumour' , 'tumor' , 'microRNA-145' , 'microrna-145' , 'miRNA-145' , 'miR-145' , 'survival' , 'recurrence' , 'relapse' , 'metastasis' , and 'prognosis'. Studies were considered eligible for further evaluation when they met the following criteria: studies that 1) focused on patients with any malignant neoplasmI and 2) investigated the association between miR-145 expression and prognosis outcomes. In addition, the bibliographies of all eligible studies were reviewed for additional relevant publications to supplement our literature search. When studies deriving from the same series of study subjects were reported in multiple publications, only the most recent and the most complete studies were used for the meta-analysis.

To fit the eligible criteria, selected studies had to be published in English, had to focus on human malignant tumors, and had to have performed stratified analyses on patient prognoses using the dichotomous expression levels of miR-145. Studies lacking the key data of hazard ratios (HRs) or confidence intervals (CIs), without survival curves, were not analyzed. A flow diagram of the study selection process is presented in Figure [2](#Fig2){ref-type="fig"}.Figure 2**Flow diagram of the study selection process.**

Extracted data elements included the following: 1) first author name and publication year; 2) characteristics of the studied population, including patient nationality, ethnicity, disease, pathological type, and sample category; 3) detection method and cut-off definition; 4) follow-up time; and 5) HRs of elevated miR-145 expression for overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), metastasis-free survival (MFS), and progression-free survival (PFS), along with their 95% CIs and *P* values. If HRs and 95% CIs were not directly reported in publications, the total numbers of cases and deaths in each group were extracted to calculate HRs \[[@CR15]\]. If only Kaplan-Meier curves were available, data were extracted from graphical survival plots to extrapolate HRs and 95% CIs, using previously described methods \[[@CR16], [@CR17]\]. All the aforementioned data are comprehensively detailed in Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}.Table 1**Main characteristics of studies included in the meta-analysis**First author, year of publication, and referencePatient country of originDominant ethnicityStudy designMalignant diseaseMain type of pathologyDetected sampleSurvival analysisSource of HRMaximum follow-up, monthsLee, 2013 \[[@CR5]\]USAWhiteRBrain gliomaGlioblastomaTissueOSReported120Saija, 2013 \[[@CR6]\]FinlandWhiteRBrain gliomaGlioblastomaTissueOSSC135Campayo, 2013 \[[@CR7]\]SpainWhiteRNSCLCAdeno/SCCTissueRFSSC36Yu, 2013 \[[@CR11]\]ChinaAsianRHNCSCCTissueOSSC60Avgeris, 2013 \[[@CR20]\]GreeceWhiteRProstate cancerAdenoTissueDFSReported72Tang, 2013 \[[@CR21]\]ChinaAsianROsteosarcomaSarcomaTissueOS/DFSReported152Tanaka, 2013 \[[@CR22]\]JapanAsianREsophageal cancerSCCSerumPFS^a^SC39Speranza, 2012 \[[@CR23]\]ItalyWhiteRBrain gliomaGlioblastomaTissueOSSC18Kang, 2012 \[[@CR24]\]KoreaAsianRProstate cancerAdenoTissueRFSReported55Schee, 2012 \[[@CR25]\]NorwayWhiteRCRCAdenoTissueMFSSC60Law, 2012 \[[@CR9]\]ChinaAsianRHCCAdenoTissueDFSSC144Ko, 2012 \[[@CR12]\]CanadaWhiteREsophageal cancerSCCTissueDFSSC32Huang, 2012 \[[@CR26]\]ChinaAsianRCervical cancerSmall cell carcinomaTissueOSSC70Marchini, 2011 \[[@CR27]\]ItalyWhiteREOCAdenoTissueOS/PFSReported143Radojicic, 2011 \[[@CR28]\]GreeceWhiteRBreast cancerAdenoTissueOS/DFSSC120Leite, 2011 \[[@CR13]\]BrazilWhiteRProstate cancerAdenoTissueRFSReported122Hamano, 2011 \[[@CR29]\]JapanAsianREsophageal cancerSCCTissueOSSC97Drebber, 2011 \[[@CR30]\]GermanyWhiteRRectal cancerAdenoTissueOSSC72Adeno, adenocarcinoma; CRC, colorectal cancer; DFS, disease-free surviva; EOC, epithelial ovarian cancer; HCC, hepatocellular carcinoma; HNC, head and neck cancer; HR, hazard ratio; MFS, metastasis-free survival; NSCLC, non-small cell lung cancer; OS, overall survival; P, prospective; PFS, progression-free survival; R, retrospective; RCC, renal cell carcinoma; RFS, relapse-free survival; SC, survival curve; SCC, squamous cell carcinoma.^a^PFS included any of the following: DFS, MFS or RFS.Table 2**Patient survival or disease progression associated with miR-145 expression in analyzed studies**First author, year of publication, and referenceAssay methodCut-off valueCases, nOSPFS^a^High expressionLow expressionHR (95% CI)***P***HR (95% CI)***P***Lee 2013 \[[@CR5]\]qRT-PCRMeanNMNM0.84 (0.74 to 0.97) (M)^b^0.017NMNMSaija 2013 \[[@CR6]\]MicroarrayThree-fold215530.67 (0.49 to 0.92) (U)^b^\<0.01NMNMCampayo 2013 \[[@CR7]\]qRT-PCRMean5614NMNM0.30 (0.12 to 0.73) (M)^b^0.015Yu 2013 \[[@CR11]\]qRT-PCRTwo-fold1251250.21 (0.14 to 0.31) (U)^b^\<0.01NMNMAvgeris 2013 \[[@CR20]\]qRT-PCRMean3527NMNM0.79 (0.31 to 2.04) (M)0.629Tang 2013 \[[@CR21]\]qRT-PCRMedian77890.28 (0.11 to 0.91) (M)0.0100.24 (0.09 to 0.83) (M)0.008Tanaka 2013 \[[@CR22]\]qRT-PCRMedian3232NMNM0.89 (0.38 to 2.09) (U)^b^0.809Speranza 2012 \[[@CR23]\]qRT-PCRMedian870.23 (0.06 to 0.83) (U)^b^0.018NMNMKang 2012 \[[@CR24]\]qRT-PCRMedianNMNMNMNM0.68 (0.22 to 2.14) (U)0.510Schee 2012 \[[@CR25]\]qRT-PCRMedian9697NMNM1.41 (0.76 to 2.59) (U)^b^0.290Law 2012 \[[@CR9]\]qRT-PCR1.5-fold1532NMNM0.22 (0.09 to 0.57) (U)^b^\<0.05Ko 2012 \[[@CR12]\]qRT-PCRTwo-fold1312NMNM2.56 (1.06 to 6.18) (U)^b^0.037Huang 2012 \[[@CR26]\]qRT-PCRMean22220.47 (0.17 to 1.33) (M)^b^0.072NMNMMarchini 2011 \[[@CR27]\]qRT-PCRMedianNMNM0.14 (0.03 to 0.75) (M)0.0222.24 (0.47 to 10.59) (M)0.309Radojicic 2011 \[[@CR28]\]qRT-PCRMean38491.19 (0.58 to 2.45) (U)^b^0.8241.04 (0.52 to 2.09) (U)^b^0.882Leite 2011 \[[@CR13]\]qRT-PCRMeanNMNMNMNM3.35 (1.32 to 8.50) (M)0.011Hamano 2011 \[[@CR29]\]qRT-PCRMedian49490.58 (0.33 to 0.99) (U)^b^0.023NMNMDrebber 2011 \[[@CR30]\]qRT-PCRMedian35150.38 (0.11 to 1.31) (U)^b^0.244NMNMCI, confidence interval; DFS, disease-free survival; HR, hazard ratio; M, multivariate analysis; MFS, metastasis-free survival; NM, not mentioned; OS, overall survival; PFS, progression-free survival; qRT-PCR, quantitative real-time PCR; RFS, relapse-free survival; U, univariate analysis.^a^PFS included any of the following: DFS, MFS or RFS.^b^HR and 95% CI calculated by survival curve.

Statistical analysis {#Sec4}
--------------------

The aggregation of HRs and 95% CIs were calculated following Tierney method \[[@CR17]\]. Forest plots were used to estimate the effect of miR-145 expression on patient survival and disease progress. Heterogeneity test for pooled HRs was verified by Cochran Q-test and Higgins I-squared statistic (I^2^). Heterogeneity was considered statistically significant at *P* \< 0.1 or if the percentage of I^2^ was greater than 50%; if so, the random-effects model (DerSimonian and Laird method) was applied, otherwise, the fixed-effects model (Mantel-Haenszel test) was used \[[@CR18]\]. In addition, we also executed stratified analyses to minimize the influence of heterogeneity by classifying analyzed studies into subgroups based on similar characteristics. Publication bias was estimated by Egger linear regression test with a funnel plot \[[@CR19]\]. All *P* values were two-sided and a *P* \< 0.05 was considered statistically significant. All statistical analyses were conducted with Stata® (v11; StataCorp LP, College Station, TX, USA).

Results {#Sec5}
=======

Summary of analyzed studies {#Sec6}
---------------------------

In total, 447 studies focusing on the relationship between miR-145 and cancer were identified from an initial online literature search, and 363 studies were excluded by manual screening of titles and abstracts. The full text of the remaining 84 studies was further evaluated, and finally, 18 studies \[[@CR5]--[@CR7], [@CR9], [@CR11]--[@CR13], [@CR20]--[@CR30]\] were considered eligible for this meta-analysis (Table [1](#Tab1){ref-type="table"}). The selection process and excluding reasons of candidate studies are shown in detail in Figure [2](#Fig2){ref-type="fig"}.

Of the 18 included studies, 11 studies in our meta-analysis were carried out with White subjects, and 7 with Asian subjects. Quantitative reverse transcription PCR (qRT-PCR) was used to measure miR-145 expression in 17 studies, while the remaining study used microarray. The malignant neoplasms studied consisted of glioma, non-small cell lung cancer (NSCLC), head and neck cancer (HNC), prostate cancer (PCa), osteosarcoma, HCC, and colorectal, esophageal, cervical, breast, and ovarian cancers. The pathological types comprised glioblastoma, adenocarcinoma, small cell carcinoma, sarcoma, and squamous cell carcinoma (SCC). Seven of the analyzed studies reported the OS of patients, eight focused on PFS (including RFS, DFS, and MFS), and three investigated both OS and PFS. All of the analyzed studies were retrospective, and maximal follow-up time ranged from 18 to 152 months. The main characteristics of analyzed studies are systematically listed in Table [1](#Tab1){ref-type="table"} and Table [2](#Tab2){ref-type="table"}.

Overall survival associated with miR-145 expression {#Sec7}
---------------------------------------------------

Ten articles analyzed OS, and seven of these showed statistical significance (Table [2](#Tab2){ref-type="table"}). Significant heterogeneity between studies was observed (*P* \< 0.001, I^2^ = 83.9%), thus a random-effects model was applied to estimate a pooled HR along with 95% CI. Our results showed that upregulated miR-145 expression was a significant predictor of favorable OS (pooled HR = 0.47, 95% CI 0.31 to 0.72) (Table [3](#Tab3){ref-type="table"}; Figure [3](#Fig3){ref-type="fig"}A).Table 3**Patient survival or disease progression by total and stratified analyses**SubgroupOSPFS^a^nHR (95% CI)***P***valuenHR (95% CI)***P***valueTotal100.47 (0.31 to 0.72)^b^\<0.001110.87 (0.51 to 1.47)^b^0.596Subtotal by ethnicity White60.67 (0.47 to 0.95)^b^0.02671.27 (0.71 to 2.26)^b^0.420 Asian40.35 (0.19 to 0.64)^b^0.00140.43 (0.21 to 0.89)^b^0.024Subtotal by disease Brain glioma30.72 (0.52 to 0.99)^b^0.045------ Prostate cancer------31.25 (0.45 to 3.48)^b^0.671 Esophageal cancer------21.50 (0.53 to 4.22)^b^0.443Subtotal by main pathology Adeno30.47 (0.14 to 1.61)^b^0.22871.01 (0.55 to 1.89)^b^0.965 SCC20.34 (0.13 to 0.93)^b^0.03521.50 (0.53 to 4.22)^b^0.443 Glioblastoma30.72 (0.52 to 0.99)^b^0.045------OS, overall survival; PFS, progression-free survival including any of relapse-free survival (RFS), disease-free survival (DFS), and metastasis-free survival (MFS); N, number of studies; HR, hazard ratio; CI, confidence interval; SqCa, squamous carcinoma; Adeno, adenocarcinoma.^a^PFS included any of the following: DFS, MFS or RFS.^b^The HRs and 95% CIs of the analyzed studies were pooled by the random-effects model if the *P* value for heterogeneity was less than 0.10 or I^2^ was greater than 50%.Figure 3**Forest plots of merged analyses for patient survival or disease progression associated with microRNA-145 (miR-145) expression, and Begg funnel plots of publication bias test. (A)** Forest plots for overall and ethnic subtotal analyses of overall survival. Squares and horizontal lines correspond to study-specific hazard ratios (HRs) and 95% confidence intervals (CIs), respectively. The area of the squares correlates the weight, and the diamonds represent summary HRs and 95% CIs. **(B)** Forest plots for overall and ethnic subtotal analyses of progression-free survival (PFS). **(C)** Begg funnel plots of publication bias test for overall merged analysis of overall survival. Each point represents a separate study. **(D)** Begg funnel plots of publication bias test for overall merged analysis of PFS.

Furthermore, we performed stratified analyses by classifying studies into subgroups of ethnicity and main pathologic type (Table [3](#Tab3){ref-type="table"}; Figure [3](#Fig3){ref-type="fig"}A; Figure [4](#Fig4){ref-type="fig"}A). First, six studies in the White subgroup displayed a better OS associated with elevated miR-145 expression (pooled HR = 0.67, 95% CI 0.47 to 0.95) by a random-effects model (*P* = 0.032, I^2^ = 59.1%). The other four studies in Asians also showed that high miR-145 expression was significantly associated with a favorable OS (pooled HR = 0.35, 95% CI 0.19 to 0.64) using a random model (P = 0.025, I^2^ = 67.9%). Second, eight studies were divided into three main pathologic subgroups of adenocarcinoma, SCC, and glioblastoma. High miR-145 expression was found to be significantly associated with favorable OS in both SCC (pooled HR = 0.34, 95% CI 0.13 to 0.93) and glioblastoma (pooled HR = 0.72, 95% CI 0.52 to 0.99). No significant association was found for the adenocarcinoma subgroup (pooled HR = 0.47, 95% CI 0.14 to 1.61).Figure 4**Forest plots of merged analyses for patient survival or disease progression associated with microRNA-145 (miR-145) expression in different subgroups of pathologic types and malignant diseases. (A)** Forest plots for the merged analyses of overall survival in different pathological subgroups. Squares and horizontal lines correspond to study-specific hazard ratios (HRs) and 95% confidence intervals (CIs), respectively. The area of the squares correlates the weight, and the diamonds represent summary HRs and 95% CIs. **(B)** Forest plots for the merged analyses of progression-free survival (PFS) in different pathological type subgroups. **(C)** Forest plots for the merged analyses of PFS in different malignant disease subgroups.

Tumor progression associated with miR-145 expression {#Sec8}
----------------------------------------------------

We analyzed tumor progression by combining disease recurrence and metastasis. Eleven studies were included in PFS analysis, and five showed statistical significance (Table [2](#Tab2){ref-type="table"}). A random-effects model was applied to calculate the pooled HR along with 95% CI for the significant heterogeneity (P \< 0.001, I^2^ = 72.9%), but failed to show any statistical significance (pooled HR = 0.87, 95% CI 0.51 to 1.47) (Table [3](#Tab3){ref-type="table"}).

Stratified analyses displayed that high miR-145 expression was a significantly favorable prediction for tumor progression in Asian subgroup of four studies (pooled HR = 0.43, 95% CI 0.21 to 0.89) by a random-effects model (P = 0.090, I^2^ = 53.8%), but failed to show a significant association between miR-145 expression and tumor progression in White subgroup of seven studies (pooled HR = 1.27, 95% CI 0.71 to 2.26) (Table [3](#Tab3){ref-type="table"}; Figure [3](#Fig3){ref-type="fig"}B). In addition, no significant relevance was observed in subgroups of PCa (pooled HR = 1.25, 95% CI 0.45 to 3.48), adenocarcinoma (pooled HR = 1.01, 95% CI 0.55 to 1.89), and squamous carcinoma (pooled HR = 1.50, 95% CI 0.53 to 4.22) (Table [3](#Tab3){ref-type="table"}; Figure [4](#Fig4){ref-type="fig"}B; Figure [4](#Fig4){ref-type="fig"}C).

Publication bias {#Sec9}
----------------

Publication bias of total analyses for patient survival and tumor progression was evaluated by funnel plots and Egger tests. As expected, the funnel plots were symmetrical and the *P* values of the Egger test were 0.076 for OS and 0.566 for PFS, suggesting the absence of significant publication bias (Figure [3](#Fig3){ref-type="fig"}C, D).

Discussion {#Sec10}
==========

Aberrant expression of miRNAs has been found in various diseases including human carcinomas, and specific miRNAs have been shown to play crucial roles in the biological behaviors of initiation, progression, migration, and invasion of tumors \[[@CR31]--[@CR35]\]. Compared with mRNAs and proteins, miRNAs are more stable and not easily degraded. They can be detected accurately by qRT-PCR in both fresh and formalin-fixed tissues \[[@CR36]\], and can also be quantified in serum, urine, or saliva samples \[[@CR37]\]. Therefore, miRNAs are considered promising tumor biomarkers for early diagnosis and accurate prognosis, as well as potential targets for clinical treatment \[[@CR1], [@CR3], [@CR22], [@CR36], [@CR38], [@CR39]\].

Recent researches have shown that downregulation of miR-145 expression is significantly associated with poor survival and prognostic outcomes of patients with cancer \[[@CR5]--[@CR9], [@CR11], [@CR21], [@CR27], [@CR29]\]. Lee *et al*. reported that low miR-145 expression in glial tumors predicted poor prognosis, and upregulated miR-145 significantly decreased the migration and invasion of glioma cells by targeting connective tissue growth factor \[[@CR5]\]. Campayo *et al*. found that low miR-145 expression independently predicted a shorter time to relapse in patients with NSCLC \[[@CR7]\]. In addition, downregulated miR-145 expression was found in PCa tissue compared with benign prostatic hyperplasia tissue, and this was correlated with higher Gleason score, advanced clinical stage, larger tumor diameter, and higher levels of prostate-specific antigen. The loss of the anti-oncogenic miR-145 may result in higher risk of biochemical recurrence, shorter DFS, and worse OS in patients with PCa \[[@CR20]\]. In the present meta-analysis, we gathered the available evidence from all relevant studies to evaluate the prognostic values of miR-145 for malignant neoplasms. Our results demonstrated that high miR-145 expression was significantly correlated with favorable OS in overall analyses (*P* \< 0.001), but did not exhibit an obvious association with tumor progression (*P* = 0.596) (Table [3](#Tab3){ref-type="table"}). These inconsistent outcomes might hint at dissimilar potential mechanisms that affect patient survival or tumor progression.

Studies on miRNA expression profiles have indicated that downregulation of miR-145 is a common event in malignant disease \[[@CR5], [@CR21], [@CR26]\]. However, little is known about why miR-145 is often downregulated in tumors. Recent studies show several underlying mechanisms playing key roles in regulating miR-145 expression, especially in relation to p53, the central tumor suppressor. Suh *et al*. found that downregulation of miR-145 was mediated through DNA methylation and p53 mutation pathways \[[@CR40]\], which frequently occur in various malignant tumors. p53 can enhance post-transcriptional maturation of miR-145 in response to DNA damage, and transcriptionally inactive p53 mutants result in attenuation of miRNA biological processing activity and predict worse prognosis in patients with low miR-145 expression \[[@CR41]\]. Loss of miR-145 expression is also observed frequently in *KRAS*-mutated pancreatic cancer, and the downregulation of miR-145 requires Ras-responsive element-binding protein (RREB1) to repress its promoter \[[@CR42]\]. In addition, Sachdeva *et al*. suggested that a regulatory system of miR-145 involving the Akt and CCAAT/enhancer binding protein beta (C/EBP-β) may contribute to the downregulation of miR-145 in cancer cells \[[@CR43]\] (Figure [1](#Fig1){ref-type="fig"}).

Based on the respective results of the analyzed studies, we found that genetic background, pathology, or disease type seemed to have specific effects on the association of miR-145 expression and patient prognosis. In addition, both of the overall analyses for patient survival and disease progression presented significant heterogeneity. All of these data demonstrated that the pooled results of overall analyses are crude and cannot give accurate values of miR-145 for prognosis. Stratified analyses based on ethnic affiliation, pathology, or disease categories should be carried out to minimize the impact of heterogeneity.

Our stratified analyses provide further confirmation that high miR-145 expression can predict favorable OS for patients both in White and Asian subgroups, but the association in Whites (HR = 0.67) is not as strong as in Asians (HR = 0.35). In addition, the high expression of miR-145 can predict better PFS in Asians, but not in Whites. These discrepancies might be due to different hereditary backgrounds and environmental exposure because previous studies have reported diverse expression levels and prognostic values of specific miRNAs in different ethnic groups \[[@CR44]--[@CR46]\]. Pathological types also had a considerable impact on the prognostic role of miR-145. High expression of miR-145 seemed to be predict favorable OS in patients with SCC or glioblastoma but not adenocarcinoma, but these results need to be confirmed by further research.

These results indicate that miR-145 is a promising biomarker to predict prognosis for patients with cancers. However, the conclusion is not sufficiently persuasive, and needs to be further refined for several reasons. First, no independent studies for black were included in our analysis, and this omission might hinder comprehensive investigation. Second, the number of analyzed studies was not adequate, which weakens the reliability of our results and hindered the execution of some subgroup analyses. Furthermore, all the studies included in our meta-analysis were retrospective, and no prospective studies were available, which also weakens the values of pooled results. Third, although there was no evidence of obvious publication bias in this meta-analysis, there is a possibility of language bias because only studies published in English were included. In addition, the tendency for authors and journals to publish only studies with positive results may also be a source of bias. Fourth, the expression of miR-145 was detected by tissue samples in all of the analyzed articles except one, which used serum. Different results might be obtained for detection of miR-145 in peripheral blood samples. Furthermore, as a cancer biomarker, detection of miR-145 ub serum samples is more convenient, faster and more acceptable for patients to dynamically monitor their prognosis and therapeutic effects through their lifetime. Therefore, the association between patient prognosis and serum expression of miR-145 should be further investigated. Fifth, it remains unknown whether miR-145 should be used as an independent biomarker or as part of a combination of several biomarkers for predicting tumor prognosis. Using Cox proportional regression analysis, Avgeris *et al*. demonstrated that patients with PCa who had lower miR-145 expression exhibited a significantly higher risk for disease recurrence. Furthermore, this unfavorable prognosis, associated with low miR-145 expression, was independent of patient Gleason score, clinical stage, PSA levels, and age \[[@CR20]\]. Law *et al*. also reported that miR-145 independently coordinated the regulation of many components along the IGF pathway via its multigene targets, and was an independent prognostic predictor \[[@CR9]\]. By contrast, Huang *et al*. claimed that the downregulation of a combination of six miRNAs including miR-145 was significantly correlated with advanced stage, lymph node metastasis, and poor prognosis in small cell carcinoma of the cervix \[[@CR26]\]. Liu *et al*. also reported that Fascin Homolog 1 (FSCN1) could be co-regulated by miR-43 and miR-145, and suggested the combination of miR-143 and miR-145 as a potential biomarker for the prognosis of esophageal cancer \[[@CR47]\]. The combined application of miR-145 with other miRNAs might confer more specificity for predicting patient prognosis in various malignant diseases, but this hypothesis needs to be proved by more clinical research.

Conclusions {#Sec11}
===========

Our meta-analysis results indicate that high miR-145 expression is more suitable as a biomarker to predict favorable patient survival rather than to predict tumor progression, especially for SCC and glioblastoma in Asians. Given the current insufficient evidence, further investigations and more studies are needed to focus on the relationship between miR-145 expression and patient prognosis.
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